First quarter European sales and market share of Truxima (rituximab) saw a decrease that Celltrion Healthcare Co., Ltd. maintains will be temporary as it prepares to transition the product, alongside Herzuma (trastuzumab), to full-scale direct marketing in most European countries by the end of June.
Ultimately, Truxima’s European market share decreased to just 29% – having seen highs of 40% last year – something Celltrion attributed “to the preparation for the additional direct sales as well as strategically participating in tenders to secure profitability in Europe
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?